SG10201702382RA - Antineoplastic combinations of 4-anilino-3-cyanoquinolines and capecitabine - Google Patents

Antineoplastic combinations of 4-anilino-3-cyanoquinolines and capecitabine

Info

Publication number
SG10201702382RA
SG10201702382RA SG10201702382RA SG10201702382RA SG10201702382RA SG 10201702382R A SG10201702382R A SG 10201702382RA SG 10201702382R A SG10201702382R A SG 10201702382RA SG 10201702382R A SG10201702382R A SG 10201702382RA SG 10201702382R A SG10201702382R A SG 10201702382RA
Authority
SG
Singapore
Prior art keywords
cyanoquinolines
capecitabine
anilino
antineoplastic combinations
antineoplastic
Prior art date
Application number
SG10201702382RA
Inventor
Kenneth Wang
Charles Zacharchuk
Florence Binlich
Susan Quinn
Original Assignee
Wyeth Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41226678&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG10201702382R(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth Llc filed Critical Wyeth Llc
Publication of SG10201702382RA publication Critical patent/SG10201702382RA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
SG10201702382RA 2008-08-04 2009-08-04 Antineoplastic combinations of 4-anilino-3-cyanoquinolines and capecitabine SG10201702382RA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8591308P 2008-08-04 2008-08-04
US17246609P 2009-04-24 2009-04-24

Publications (1)

Publication Number Publication Date
SG10201702382RA true SG10201702382RA (en) 2017-05-30

Family

ID=41226678

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10202102855RA SG10202102855RA (en) 2008-08-04 2009-08-04 Antineoplastic combinations of 4-anilino-3-cyanoquinolines and capecitabine
SG10201702382RA SG10201702382RA (en) 2008-08-04 2009-08-04 Antineoplastic combinations of 4-anilino-3-cyanoquinolines and capecitabine

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG10202102855RA SG10202102855RA (en) 2008-08-04 2009-08-04 Antineoplastic combinations of 4-anilino-3-cyanoquinolines and capecitabine

Country Status (26)

Country Link
US (2) US8669273B2 (en)
EP (2) EP2326329B1 (en)
JP (1) JP5681108B2 (en)
KR (2) KR20140069340A (en)
CN (6) CN105963313A (en)
AU (1) AU2009279771B2 (en)
BR (1) BRPI0916694B1 (en)
CA (1) CA2730715C (en)
CY (1) CY1118602T1 (en)
DK (1) DK2326329T3 (en)
ES (1) ES2614912T3 (en)
HK (1) HK1218262A1 (en)
HR (1) HRP20170074T1 (en)
HU (1) HUE032958T2 (en)
IL (1) IL210616A (en)
LT (1) LT2326329T (en)
MX (1) MX2011001318A (en)
NZ (1) NZ590464A (en)
PL (2) PL3175853T3 (en)
PT (1) PT2326329T (en)
RU (1) RU2498804C2 (en)
SG (2) SG10202102855RA (en)
SI (1) SI2326329T1 (en)
SM (1) SMT201700084B (en)
WO (1) WO2010017163A1 (en)
ZA (1) ZA201101662B (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1848414T3 (en) 2005-02-03 2011-07-25 Gen Hospital Corp Process for the treatment of gefitinib-resistant cancer
RU2451524C2 (en) 2005-11-04 2012-05-27 Вайет Anti-tumour combinations mtor inhibitors, herceptin and/or hki-272
US8022216B2 (en) 2007-10-17 2011-09-20 Wyeth Llc Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
CA2725598C (en) 2008-06-17 2013-10-08 Wyeth Llc Antineoplastic combinations containing hki-272 and vinorelbine
NZ590464A (en) * 2008-08-04 2012-10-26 Wyeth Llc Antineoplastic combinations of the 4-anilino-3-cyanoquinoline neratinib and capecitabine
DK3000467T3 (en) 2009-04-06 2023-03-27 Wyeth Llc TREATMENT WITH NERATINIB AGAINST BREAST CANCER
EP2498751B1 (en) 2009-11-09 2019-04-03 Wyeth LLC Coated drug spheroids and uses thereof for eliminating or reducing conditions such as emesis and diarrhea
RU2015152175A (en) * 2013-06-19 2017-07-24 Ф. Хоффманн-Ля Рош Аг COMBINATION RO5503781, CAPETSITABINE AND OXALIPLATIN FOR CANCER THERAPY
KR20160007662A (en) * 2013-06-19 2016-01-20 에프. 호프만-라 로슈 아게 Combination of ro5503781 and capecitabine for cancer therapy
EP3097108B8 (en) 2014-01-23 2021-04-07 Immunolight, LLC Use of psoralen derivatives and combination therapy for treatment of cell proliferation disorders
CA2939345C (en) 2014-02-17 2022-05-31 Children's National Medical Center Method and system for providing recommendation for optimal execution of surgical procedures
JP6458007B2 (en) * 2014-04-04 2019-01-23 大鵬薬品工業株式会社 Antitumor agent and antitumor effect potentiator containing antitumor platinum complex
US20190016703A1 (en) * 2015-12-30 2019-01-17 Dana-Farber Cancer Institute, Inc. Bifunctional compounds for her3 degradation and methods of use
WO2018133838A1 (en) * 2017-01-22 2018-07-26 江苏恒瑞医药股份有限公司 Uses of egfr/her2 inhibitor combined with pyrimidine-type anti-metabolic drug
CN111110681A (en) * 2018-10-31 2020-05-08 正大天晴药业集团股份有限公司 Application of quinoline derivative and capecitabine in treatment of liver cancer
CN114761010B (en) * 2019-11-25 2024-04-16 正大天晴药业集团股份有限公司 Combined pharmaceutical composition of quinazoline derivative or salt thereof and application thereof

Family Cites Families (154)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7399A (en) 1850-05-28 charles payne
US865A (en) 1838-08-01 Improvement in fire-arms
CA1327358C (en) 1987-11-17 1994-03-01 Morio Fujiu Fluoro cytidine derivatives
WO1989006692A1 (en) 1988-01-12 1989-07-27 Genentech, Inc. Method of treating tumor cells by inhibiting growth factor receptor function
LU91067I2 (en) 1991-06-14 2004-04-02 Genentech Inc Trastuzumab and its variants and immunochemical derivatives including immotoxins
AU671491B2 (en) 1992-12-18 1996-08-29 F. Hoffmann-La Roche Ag N-oxycarbonyl substituted 5'-deoxy-5-fluorcytidines
TW254946B (en) 1992-12-18 1995-08-21 Hoffmann La Roche
NZ272608A (en) 1994-07-22 2000-05-26 Lilly Co Eli Inhibiting bone loss by administering a bisphosphonate and a second compound selected from various compounds, including 2-phenyl-3-aroylbenzothienes; bisphosphonate combination salts
US5476932A (en) 1994-08-26 1995-12-19 Hoffmann-La Roche Inc. Process for producing N4-acyl-5'-deoxy-5-fluorocytidine derivatives
GB9508538D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
GB9508565D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quiazoline derivative
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
WO1997017329A1 (en) 1995-11-07 1997-05-15 Kirin Beer Kabushiki Kaisha Quinoline derivatives and quinazoline derivatives inhibiting autophosphorylation of growth factor receptor originating in platelet and pharmaceutical compositions containing the same
US5760041A (en) 1996-02-05 1998-06-02 American Cyanamid Company 4-aminoquinazoline EGFR Inhibitors
US6002008A (en) 1997-04-03 1999-12-14 American Cyanamid Company Substituted 3-cyano quinolines
UA73073C2 (en) 1997-04-03 2005-06-15 Уайт Холдінгз Корпорейшн Substituted 3-cyan chinolines
US6251912B1 (en) 1997-08-01 2001-06-26 American Cyanamid Company Substituted quinazoline derivatives
CZ303899B6 (en) 1998-09-29 2013-06-19 Wyeth Holdings Corporation Substituted 3-cyanoquinoline, process for its preparation and pharmaceutical composition containing thereof
US6297258B1 (en) 1998-09-29 2001-10-02 American Cyanamid Company Substituted 3-cyanoquinolines
US6288082B1 (en) 1998-09-29 2001-09-11 American Cyanamid Company Substituted 3-cyanoquinolines
US6432979B1 (en) 1999-08-12 2002-08-13 American Cyanamid Company Method of treating or inhibiting colonic polyps and colorectal cancer
CZ20022332A3 (en) 2000-01-07 2003-01-15 Transform Pharmaceuticals, Inc. Sample assembly
US6384051B1 (en) 2000-03-13 2002-05-07 American Cyanamid Company Method of treating or inhibiting colonic polyps
US7306801B2 (en) 2000-05-15 2007-12-11 Health Research, Inc. Methods of therapy for cancers characterized by overexpression of the HER2 receptor protein
CA2416976C (en) 2000-08-11 2008-05-20 Wyeth Treatment of estrogen receptor positive carcinoma with a rapamycin and an antiestrogen
TWI286074B (en) 2000-11-15 2007-09-01 Wyeth Corp Pharmaceutical composition containing CCI-779 as an antineoplastic agent
TWI296196B (en) 2001-04-06 2008-05-01 Wyeth Corp Antineoplastic combinations
HUP0304093A3 (en) 2001-04-06 2008-08-28 Wyeth Corp Antineoplastic combinations containing and mtor inhibitor and an antimetabolic antineoplastic agent and pharmaceutical compositions containing them
TWI233359B (en) 2001-04-06 2005-06-01 Wyeth Corp Pharmaceutical composition for treating neoplasm
US20020198137A1 (en) 2001-06-01 2002-12-26 Wyeth Antineoplastic combinations
SG153647A1 (en) 2001-06-01 2009-07-29 Wyeth Corp Antineoplastic combinations
UA77200C2 (en) 2001-08-07 2006-11-15 Wyeth Corp Antineoplastic combination of cci-779 and bkb-569
TW200300348A (en) 2001-11-27 2003-06-01 American Cyanamid Co 3-cyanoquinolines as inhibitors of egf-r and her2 kinases
TWI275390B (en) 2002-04-30 2007-03-11 Wyeth Corp Process for the preparation of 7-substituted-3- quinolinecarbonitriles
ATE547708T1 (en) 2002-06-05 2012-03-15 Cedars Sinai Medical Center METHOD FOR MANAGING KINASIS INHIBITOR THERAPY
AU2003248813A1 (en) 2002-07-05 2004-01-23 Beth Israel Deaconess Medical Center Combination of mtor inhibitor and a tyrosine kinase inhibitor for the treatment of neoplasms
US20040209930A1 (en) 2002-10-02 2004-10-21 Carboni Joan M. Synergistic methods and compositions for treating cancer
CL2004000016A1 (en) 2003-01-21 2005-04-15 Wyeth Corp 4-AMINO-2-BUTENOYL CHLORIDE COMPOUND OR A PHARMACEUTICALLY ACCEPTABLE SALT OF THE SAME; PROCEDURE TO PREPARE SUCH COMPOUND, USEFUL AS INTERMEDIARY IN THE SYNTHESIS OF INHIBITING COMPOUNDS OF PROTEIN QUINASA TIROSINA.
UA83484C2 (en) 2003-03-05 2008-07-25 Уайт Method for treating breast cancer using combination of rapamycin derivative and aromatase inhibitor, pharmaceutical composition
DK1615640T3 (en) 2003-04-22 2007-03-12 Wyeth Corp Antineoplastic Compositions
US20050043233A1 (en) 2003-04-29 2005-02-24 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis
CL2004001834A1 (en) 2003-07-23 2005-06-03 Bayer Pharmaceuticals Corp COMPOUND 4- {4- [3- (4-CHLORO-3-TRIFLUOROMETILFENIL) -UREIDO] -3-FLUOROFENOXI} -PIRIDIN-2-METHYLAMIDE, RAF INHIBITOR, VEGFR, P38 AND PDGFR KINASES, ITS SALTS; PHARMACEUTICAL COMPOSIICON; PHARMACEUTICAL COMBINATION; AND ITS USE TO TREAT HYPERPROL DISORDERS
US20050025825A1 (en) 2003-07-31 2005-02-03 Xanodyne Pharmacal, Inc. Tranexamic acid formulations with reduced adverse effects
RU2006106267A (en) * 2003-08-01 2006-07-27 Уайт Холдингз Корпорейшн (Us) APPLICATION OF THE KINASE INHIBITOR RECEPTOR EPIDERMAL GROWTH FACTOR AND CYTOTOXIC AGENTS FOR TREATMENT AND INHIBITION OF CANCER
EP1660453A2 (en) 2003-08-19 2006-05-31 Wyeth Holdings Corporation Process for the preparation of 4-amino-3-quinolinecarbonitriles
US7399865B2 (en) 2003-09-15 2008-07-15 Wyeth Protein tyrosine kinase enzyme inhibitors
MXPA06002846A (en) 2003-09-15 2006-06-14 Wyeth Corp Substituted quinolines as protein tyrosine kinase enzyme inhibitors.
TWI372066B (en) 2003-10-01 2012-09-11 Wyeth Corp Pantoprazole multiparticulate formulations
US20050142192A1 (en) 2003-10-15 2005-06-30 Wyeth Oral administration of [2-(8,9-dioxo-2,6-diazabicyclo[5.2.0]non-1(7)-en-2-yl)alkyl] phosphonic acid and derivatives
WO2005044091A2 (en) 2003-11-05 2005-05-19 Board Of Regents, The University Of Texas System Diagnostic and therapeutic methods and compositions involving pten and breast cancer
AR046639A1 (en) 2003-11-21 2005-12-14 Schering Corp ANTI-IGFR1 ANTIBODY THERAPEUTIC COMBINATIONS
AR047988A1 (en) 2004-03-11 2006-03-15 Wyeth Corp ANTI -OPLASTIC COMBINATIONS OF CCI-779 AND RITUXIMAB
EP2423331B1 (en) 2004-03-31 2019-05-08 The General Hospital Corporation Method to determine responsiveness of cancer to epidermal growth factor receptor targeting treatments
JP2008507264A (en) 2004-07-23 2008-03-13 アストラゼネカ アクチボラグ Method for predicting tumor responsiveness to drugs to ERBB receptors
US20060058311A1 (en) 2004-08-14 2006-03-16 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation
TW200616612A (en) 2004-10-08 2006-06-01 Wyeth Corp Method for the teatment of polycystic kidney disease field of invention
JP2008515984A (en) 2004-10-13 2008-05-15 ワイス Analogs of 17-hydroxy wortmannin as PI3K inhibitors
US20080254497A1 (en) 2004-10-15 2008-10-16 Monogram Biosciences, Inc. Response Predictors for Erbb Pathway-Specific Drugs
GB0501999D0 (en) 2005-02-01 2005-03-09 Sentinel Oncology Ltd Pharmaceutical compounds
DK1848414T3 (en) 2005-02-03 2011-07-25 Gen Hospital Corp Process for the treatment of gefitinib-resistant cancer
WO2006081985A1 (en) * 2005-02-04 2006-08-10 F. Hoffmann-La Roche Ag Combined treatment with an n4-(substituted-oxycarbonyl)-5’-deoxy-5-fluorocytidine derivative and an epidermal growth factor receptor kinase inhibitor
DE602006021401D1 (en) 2005-02-28 2011-06-01 Eisai R&D Man Co Ltd NEW COMBINED USE OF A SULFONAMIDE COMPOUND FOR THE TREATMENT OF CANCER
US8105768B2 (en) 2005-03-09 2012-01-31 Abbott Laboratories Methods of identifying patients for treatment with HER-2/neu inhibitors based on detection of HER-2/neu and TOP2A gene copy number
GB0504994D0 (en) 2005-03-11 2005-04-20 Biotica Tech Ltd Novel compounds
US20060235006A1 (en) * 2005-04-13 2006-10-19 Lee Francis Y Combinations, methods and compositions for treating cancer
MX2007012662A (en) 2005-04-14 2008-04-04 Wyeth Corp Use of an epidermal growth factor receptor kinase inhibitor (egfr) in gefitinib resistant patients.
WO2006116016A2 (en) 2005-04-21 2006-11-02 The Regents Of The University Of California Molecular determinants of egfr kinase inhibitor response in glioblastoma
CN101166532B (en) 2005-04-28 2011-06-22 惠氏公司 Micronized tanaproget, compositions, and methods of preparing the same
US20080193448A1 (en) * 2005-05-12 2008-08-14 Pfizer Inc. Combinations and Methods of Using an Indolinone Compound
CN101180269A (en) 2005-05-25 2008-05-14 惠氏公司 Method of preparing 3-cyano-quinolines and intermediates made thereby
RU2007143161A (en) 2005-05-25 2009-07-10 Вайет (Us) METHODS FOR SYNTHESIS OF SUBSTITUTED 3-CYANOCHINES AND THEIR PRODUCTS
DE102005053679A1 (en) 2005-06-24 2006-12-28 Bayer Healthcare Ag Use of floroquinolones for producing medicament to treat and/or prevent e.g. immunosuppresion, viral and bacterial infections, respiratory tract diseases, digestive tract diseases, and influenza diseases
AR054833A1 (en) 2005-07-15 2007-07-18 Wyeth Corp DOSAGE FORMS OF DELAYED ORAL DELAY Highly bi-available O-DEMETILVENLAFAXINA SUCCINATE
JP5066446B2 (en) 2005-08-01 2012-11-07 エーザイ・アール・アンド・ディー・マネジメント株式会社 Methods for predicting the effects of angiogenesis inhibitors
EP1925676A4 (en) 2005-08-02 2010-11-10 Eisai R&D Man Co Ltd Method for assay on the effect of vascularization inhibitor
AU2005337051A1 (en) 2005-10-05 2007-04-12 Astrazeneca Uk Limited Method to predict or monitor the response of a patient to an ErbB receptor drug
US20110052570A1 (en) 2005-10-26 2011-03-03 Children's Medical Center Corporation Method to prognose response to anti-egfr therapeutics
RU2451524C2 (en) 2005-11-04 2012-05-27 Вайет Anti-tumour combinations mtor inhibitors, herceptin and/or hki-272
US20070105887A1 (en) 2005-11-04 2007-05-10 Wyeth Antineoplastic combinations of temsirolimus and sunitinib malate
CA2629249C (en) 2005-11-11 2015-05-05 Boehringer Ingelheim International Gmbh Combination treatment of cancer comprising egfr/her2 inhibitors
DK1951274T3 (en) 2005-11-24 2010-02-01 Aicuris Gmbh & Co Kg Parapoxviruses in combination with classical cytotoxic chemotherapeutic agents such as biochemotherapy for the treatment of cancer
JP2007145745A (en) * 2005-11-25 2007-06-14 Osaka Univ Lung cancer medicine containing src family tyrosine kinase inhibitor for inhibiting variant egfr downstream signal and utilization thereof
WO2007075794A2 (en) 2005-12-22 2007-07-05 Wyeth Oral formulations comprising tigecycline
WO2007095038A2 (en) 2006-02-09 2007-08-23 Novartis Ag Mutations and polymorphisms of erbb2
BRPI0710675A2 (en) * 2006-04-07 2011-08-23 Novartis Ag use of c-src inhibitors in combination with a pyrimidylaminobenzamide compound for the treatment of leukemia
TW200806282A (en) 2006-05-05 2008-02-01 Wyeth Corp Solid dosage formulations
US8700335B2 (en) 2006-05-18 2014-04-15 Caris Mpi, Inc. System and method for determining individualized medical intervention for a disease state
TW200808728A (en) 2006-05-23 2008-02-16 Wyeth Corp Method of preparing 4-halogenated quinoline intermediates
ES2427924T3 (en) 2006-06-30 2013-11-04 Merck Sharp & Dohme Corp. IGFBP2 biomarker
EP2068880B1 (en) 2006-09-18 2012-04-11 Boehringer Ingelheim International GmbH Method for treating cancer harboring egfr mutations
EP2077819A4 (en) 2006-09-28 2011-05-25 Follica Inc Methods, kits, and compositions for generating new hair follicles and growing hair
WO2008043576A1 (en) 2006-10-13 2008-04-17 Medigene Ag Use of oncolytic viruses and antiangiogenic agents in the treatment of cancer
WO2008076257A2 (en) 2006-12-13 2008-06-26 Schering Corporation Treating cancer with anti-igflr antibody 19d12 = sch 717454
EP2104501B1 (en) 2006-12-13 2014-03-12 Merck Sharp & Dohme Corp. Methods of cancer treatment with igf1r inhibitors
WO2008076143A1 (en) * 2006-12-18 2008-06-26 Osi Pharmaceuticals, Inc. Combination of igfr inhibitor and anti-cancer agent
MX2009006700A (en) 2006-12-21 2009-06-30 Vertex Pharma 5-cyan0-4- (pyrrolo [2, 3b] pyridine-3-yl) -pyrimidine derivatives useful as protein kinase inhibitors.
CL2008000095A1 (en) 2007-01-12 2008-05-16 Wyeth Corp COMPOSITION OF TABLET IN TABLET THAT INCLUDES A CENTRAL TABLET WITH STROGENS, A FILLER / DILUENT, A FILLER / BINDER, A POLYMER COMPONENT AND A LAYER OF EXTERNAL TABLET COMPRESSED WITH THERAPYUTICAL AGENTS / A FILLER
WO2008091701A2 (en) 2007-01-25 2008-07-31 Dana-Farber Cancer Institute Use of anti-egfr antibodies in treatment of egfr mutant mediated disease
TW200836774A (en) 2007-02-01 2008-09-16 Takeda Pharmaceutical Solid preparation
WO2008121467A2 (en) 2007-02-28 2008-10-09 Dana-Farber Cancer Institute, Inc. Combination therapy for treating cancer
GB0706633D0 (en) 2007-04-04 2007-05-16 Cyclacel Ltd Combination
EP2076289B1 (en) 2007-04-13 2014-11-12 Dana-Farber Cancer Institute, Inc. Methods for treating cancer resistant to erbb therapeutics
WO2008130910A1 (en) 2007-04-19 2008-10-30 Wellstat Biologics Corporation Detection her-2/neu protein from non-isolated circulating cancer cells and treatment
WO2008136838A1 (en) 2007-05-04 2008-11-13 Trustees Of Dartmouth College Novel amide derivatives of cddo and methods of use thereof
US20110014117A1 (en) 2007-06-28 2011-01-20 Schering Corporation Anti-igf1r
DK2194987T3 (en) 2007-09-10 2016-08-15 Boston Biomedical Inc Newly known group of stat3 signaling pathway inhibitors and cancer stem cell inhibitors
EP2205076A4 (en) 2007-09-24 2010-12-29 Tragara Pharmaceuticals Inc Combination therapy for the treatment of cancer using cox-2 inhibitors and dual inhibitors of egfr ýerbb1¨and her-2 ýerbb2¨
US8022216B2 (en) 2007-10-17 2011-09-20 Wyeth Llc Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
US8216571B2 (en) 2007-10-22 2012-07-10 Schering Corporation Fully human anti-VEGF antibodies and methods of using
JP2011502571A (en) 2007-11-05 2011-01-27 ピュアテック ベンチャーズ Methods, kits, and compositions for administering pharmaceutical compounds
CA2709827A1 (en) 2007-12-18 2009-06-25 Schering Corporation Biomarkers for sensitivity to anti-igf1r therapy
US20100297118A1 (en) 2007-12-27 2010-11-25 Macdougall John Therapeutic Cancer Treatments
WO2009105234A2 (en) 2008-02-19 2009-08-27 Combinatorx, Incorporated Methods and compositions for the treatment of disorders associated with defects of the cystic fibrosis transmembrane conductance regulator gene or protein
DK2602623T3 (en) 2008-02-25 2015-11-09 Nestec Sa METHOD OF DETECTING INTRACELLULAR TRUNCTED RECEPTORS
WO2009111073A2 (en) 2008-03-06 2009-09-11 Odyssey Thera, Inc. High-content and high throughput assays for identification of lipid-regulating pathways, and novel therapeutic agents for lipid disorders
JP2011515478A (en) 2008-03-25 2011-05-19 シェーリング コーポレイション Methods for treating or preventing colorectal cancer
EP2977468B1 (en) 2008-03-27 2019-06-19 Vascular Biosciences, Inc. Methods of novel therapeutic candidate identification through gene expression analysis in pulmonary arterial hypertension
US20090246198A1 (en) 2008-03-31 2009-10-01 Takeda Pharmaceutical Company Limited Mapk/erk kinase inhibitors and methods of use thereof
US20110182888A1 (en) 2008-04-08 2011-07-28 Peter Ordentlich Administration of an Inhibitor of HDAC, an Inhibitor of HER-2, and a Selective Estrogen Receptor Modulator
EP2279197B1 (en) 2008-04-18 2014-11-05 Reata Pharmaceuticals, Inc. Antioxidant inflammation modulators: oleanolic acid derivatives with saturation in the c-ring
JP5529851B2 (en) 2008-04-18 2014-06-25 リアタ ファーマシューティカルズ インコーポレイテッド Antioxidative inflammation modulator: oleanolic acid derivative with amino modification and other modifications in C-17
RS55631B1 (en) 2008-04-18 2017-06-30 Reata Pharmaceuticals Inc Antioxidant inflammation modulators: c-17 homologated oleanolic acid derivatives
MX2010011435A (en) 2008-04-18 2011-01-25 Reata Pharmaceuticals Inc Compounds including an anti-inflammatory pharmacore and methods of use.
WO2009146216A2 (en) 2008-04-18 2009-12-03 Reata Pharmaceuticals. Inc. Antioxidant inflammation modulators: novel derivatives of oleanolic acid
WO2009137378A2 (en) 2008-05-05 2009-11-12 Schering Corporation Sequential administration of chemotherapeutic agents for treatment of cancer
WO2009151910A2 (en) 2008-05-25 2009-12-17 Wyeth Combination product of receptor tyrosine kinase inhibitor and fatty acid synthase inhibitor for treating cancer
CA2725598C (en) 2008-06-17 2013-10-08 Wyeth Llc Antineoplastic combinations containing hki-272 and vinorelbine
CA2731650A1 (en) 2008-07-22 2010-01-28 Tadashi Honda Monocyclic cyanoenones and methods of use thereof
NZ590464A (en) 2008-08-04 2012-10-26 Wyeth Llc Antineoplastic combinations of the 4-anilino-3-cyanoquinoline neratinib and capecitabine
US20100069340A1 (en) 2008-09-11 2010-03-18 Wyeth Pharmaceutical compositions of an src kinase inhibitor and an aromatase inhibitor
EP3075864A1 (en) 2008-10-14 2016-10-05 Caris MPI, Inc. Gene and gene expressed protein targets depicting biomarker patterns and signature sets by tumor type
WO2010048477A2 (en) 2008-10-24 2010-04-29 Wyeth Llc Improved process for preparation of coupled products from 4-amino-3-cyanoquinolines using stabilized intermediates
CA2741050A1 (en) 2008-11-07 2010-05-14 Santaris Pharma A/S Erbb-3 (her3)-selective combination therapy
WO2010085845A1 (en) 2009-01-28 2010-08-05 The University Of Queensland Cancer therapy and/or diagnosis
TW201032796A (en) 2009-02-04 2010-09-16 Bipar Sciences Inc Treatment of lung cancer with a PARP inhibitor in combination with a growth factor inhibitor
WO2010098627A2 (en) 2009-02-27 2010-09-02 한올바이오파마주식회사 Pharmaceutical preparation
JP5793428B2 (en) 2009-03-11 2015-10-14 オークランド ユニサーヴィスィズ リミテッド Prodrug form of kinase inhibitors and their use in therapy
DK3000467T3 (en) 2009-04-06 2023-03-27 Wyeth Llc TREATMENT WITH NERATINIB AGAINST BREAST CANCER
AR076053A1 (en) 2009-04-14 2011-05-18 Schering Corp DERIVATIVES OF PIRAZOLO [1,5-A] PYRIMIDINE AS MOTOR INHIBITORS
WO2010124009A2 (en) 2009-04-21 2010-10-28 Schering Corporation Fully human anti-vegf antibodies and methods of using
ES2659725T3 (en) 2009-05-05 2018-03-19 Dana-Farber Cancer Institute, Inc. EGFR inhibitors and disorder treatment procedure
AU2010266342A1 (en) 2009-07-02 2012-01-19 Wyeth Llc 3-cyanoquinoline tablet formulations and uses thereof
WO2011008054A2 (en) 2009-07-17 2011-01-20 한올바이오파마주식회사 Butyric acid salt of n,n-dimethyl imidocarbon imidic diamide, method of preparing same, and pharmaceutical compositions and combinations containing same
WO2011008053A2 (en) 2009-07-17 2011-01-20 한올바이오파마주식회사 Propionate of n,n-dimethyl imidocarbon imidic diamide, method of preparing same, and pharmaceutical compositions and combinations containing same
WO2011025271A2 (en) 2009-08-25 2011-03-03 한올바이오파마주식회사 Metformin ascorbate, method for preparing same, pharmaceutical composition comprising same, and combined formulation comprising same
WO2011025269A2 (en) 2009-08-25 2011-03-03 한올바이오파마주식회사 Metformin taurate, method for preparing same, pharmaceutical composition comprising same, and combined formulation comprising same
KR20110021691A (en) 2009-08-25 2011-03-04 한올바이오파마주식회사 Metformin methanesulfonic acidsalt, preparation thereof, pharmaceutical composition comprising the same and combined formulation comprising the same
AU2010302961A1 (en) 2009-10-01 2012-04-19 Csl Limited Method of treatment of philadelphia chromosome positive leukaemia
EP2498751B1 (en) 2009-11-09 2019-04-03 Wyeth LLC Coated drug spheroids and uses thereof for eliminating or reducing conditions such as emesis and diarrhea
EP3566697A1 (en) 2009-11-09 2019-11-13 Wyeth LLC Tablet formulations of neratinib maleate
LT3351558T (en) 2009-11-13 2020-06-10 Daiichi Sankyo Europe Gmbh Material and methods for treating or preventing her-3 associated diseases
US20130012465A1 (en) 2009-12-07 2013-01-10 Boehringer Ingelheim International Gmbh Bibw 2992 for use in the treatment of triple negative breast cancer
WO2011070499A1 (en) 2009-12-11 2011-06-16 Wyeth Llc Phosphatidylinositol-3-kinase pathway biomarkers
EP2524231B1 (en) 2010-01-13 2017-06-28 Wyeth LLC A CUT-POINT IN PTEN PROTEIN EXPRESSION THAT ACCURATELY IDENTIFIES TUMORS AND IS PREDICTIVE OF DRUG RESPONSE TO A PAN-ErbB INHIBITOR

Also Published As

Publication number Publication date
NZ590464A (en) 2012-10-26
BRPI0916694B1 (en) 2021-06-08
US9265784B2 (en) 2016-02-23
KR20140069340A (en) 2014-06-09
EP2326329B1 (en) 2017-01-11
JP2011529968A (en) 2011-12-15
KR20110036604A (en) 2011-04-07
ES2614912T3 (en) 2017-06-02
IL210616A0 (en) 2011-03-31
MX2011001318A (en) 2011-03-04
DK2326329T3 (en) 2017-02-20
EP2326329A1 (en) 2011-06-01
CN105147713A (en) 2015-12-16
CN102202667A (en) 2011-09-28
US8669273B2 (en) 2014-03-11
WO2010017163A1 (en) 2010-02-11
PL2326329T3 (en) 2017-07-31
CA2730715A1 (en) 2010-02-11
SG10202102855RA (en) 2021-05-28
SI2326329T1 (en) 2017-06-30
US20100113474A1 (en) 2010-05-06
SMT201700084B (en) 2017-03-08
CN113209121A (en) 2021-08-06
AU2009279771B2 (en) 2015-05-14
PL3175853T3 (en) 2024-03-25
CN115990181A (en) 2023-04-21
JP5681108B2 (en) 2015-03-04
AU2009279771A1 (en) 2010-02-11
HUE032958T2 (en) 2017-11-28
BRPI0916694A2 (en) 2015-11-17
HRP20170074T1 (en) 2017-03-24
EP3175853A1 (en) 2017-06-07
RU2498804C2 (en) 2013-11-20
CN109464445A (en) 2019-03-15
CY1118602T1 (en) 2017-07-12
CN105963313A (en) 2016-09-28
IL210616A (en) 2015-10-29
KR101434009B1 (en) 2014-08-25
US20140171384A1 (en) 2014-06-19
PT2326329T (en) 2017-02-14
RU2011102797A (en) 2012-09-10
EP3175853B1 (en) 2023-11-01
HK1218262A1 (en) 2017-02-10
ZA201101662B (en) 2011-11-30
CA2730715C (en) 2013-10-01
LT2326329T (en) 2017-05-25

Similar Documents

Publication Publication Date Title
HK1218262A1 (en) Antineoplastic combinations of 4-anilino-3-cyanoquinolines and capecitabine 4--3-
HK1254895A1 (en) Benzylbenzene derivatives and methods of use
EG27167A (en) Microemulsifiers and methods of making and using same
IL211042A0 (en) Imidazopyridin-2-one derivatives and uses thereof
ZA201103635B (en) Azaquinolinone derivatives and uses thereof
IL210153A0 (en) Nutrigenomics methods and compositions
IL212822A0 (en) Anti-cxcr1 compositions and methods
IL213974A0 (en) Isoxazole-isoxazole and isoxazole-isothiazole derivatives
ZA201109034B (en) Aminopyrrolidinone derivatives and uses thereof
GB0819530D0 (en) Methods and compositions
IL208771A0 (en) Iminopyridine derivatives and use thereof
HK1161720A1 (en) Dihydroetorphines and their preparation
EP2370414A4 (en) Preparation of capecitabine
ZA201005482B (en) New macrolides and their use
IL206951A0 (en) 3-alkyl-piperazine derivatives and uses thereof
EP2274294A4 (en) 5-demethoxyfumagillol and derivatives thereof
GB0813359D0 (en) Halfin and/or platerfin
GB0811250D0 (en) Methods and compositions
IL206950A0 (en) Aminopiperidinyl derivatives and uses thereof
PL383161A1 (en) N-N-dialkyl derivatives of 2-amino-2-deoxy-D-glucytol-6-phosphate and the manner of obtaining them
GB0803464D0 (en) Methods and compositions
GB0816534D0 (en) Compositions and methods
GB0811152D0 (en) Methods and compositions
GB0818399D0 (en) Methods and compositions